출판 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2023년01월
eClinical 솔루션 시장 : 제품 (CDMS, eCOA, CTMS, RTSM, ETMF, 분석, 안전), 배포 (웹 호스트, 라이센스 회사, 클라우드 기반), 최종 사용자 (제약, 병원, CRO), 임상 시험 단계 (단계 I, II), 지역별 – 2027년까지의 세계 예측
eClinical Solutions Market by Product (CDMS, eCOA, CTMS, RTSM, ETMF, Analytics, Safety), Delivery (Web-hosted, Licensed Enterprise, Cloud-based), End User (Pharma, Hospitals, CROs), Clinical Trial Phases (Phase I, II) & Region – Global Forecasts to 2027
페이지수 | 293 |
도표수 | 420 |
구성 | 영문조사보고서 |
가격 |
The global eClinical Solutions market is projected to reach USD 17.9 billion in 2027 from USD 9.6 billion in 2022 at a CAGR of 13.3%. Rising operational costs and regulatory requirements pertaining to clinical research studies, favorable government support & funding for clinical trials, increasing R&D expenditure on drug development by pharma-biotech companies and growing adoption of novel software solutions in clinical research are some of the major driving factors for the global eClinical solutions market.
세계 eClinical Solution 시장은 2022년 96억 달러에서 연평균 13.3% 성장하여 2027년 179억 달러에 이를 것으로 예상됩니다. eClinical 솔루션 시장은 임상 연구와 관련된 운영 비용 및 규제 요구 사항 증가, 임상 시험에 대한 우호적인 정부 지원 및 자금 지원, 제약 생명 공학 회사의 약물 개발에 대한 R&D 지출 증가 및 임상 연구에서 새로운 소프트웨어 솔루션의 채택 증가는 주요 원동력 중 일부입니다.
Web-hosted (on-demand) models segment held the largest market share in 2021
Based on delivery mode, the global eClinical solutions market is segmented into web-hosted (on-demand), licensed enterprise (on-premises), and cloud-based (SaaS) models. In 2021, the web-hosted segment accounted for the largest share (55.1%) of the global eClinical solutions market. Advantages such as easy user access, reductions in cost, and faster retrieval of data are factors driving the market growth for web-hosted eClinical solutions during the forecast period.
Phase III clinical trials is expected to register the highest growth during the forecast period
Based on clinical trial phase, the eClinical solutions market has been segmented into phase I, II, III, and IV. The phase III clinical trials segment accounted for the largest share of the eClinical solutions market in 2021 and is expected to register the highest growth during the forecast period. The significant demand for eClinical solutions in phase III clinical trials is mainly attributed to the involvement of a large patient sample population size, the globalization of clinical trials, and the rising need to increase the efficiency of clinical trials.
Pharmaceutical & biopharmaceutical companies to dominate the eClinical solutions end user segment in 2021
Based on end user, the global eClinical solutions market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, consultancy service companies, medical device manufacturers, hospitals, and academic & research institutes. The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of 38.5% of the global eClinical solutions market, by end user, in 2021. The large share of this segment can primarily be attributed to factors such as increasing applications of clinical data management and analytics software during clinical trials and the availability of R&D budgets for advanced healthcare IT software.
Asia Pacific to witness the highest growth between 2022 to 2027
In 2021, North America commanded the largest share of the eClinical solutions market, however, the Asia Pacific region is estimated to record the highest CAGR of 16.3% between 2022-2027. Increasing outsourcing of clinical trial studies by large pharmaceutical & biopharmaceutical companies, the presence of a large patient population, and low operating costs of conducting clinical trials are key factors driving the growth of the eClinical solutions market in the Asia Pacific region.
Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 33%, Tier 2 – 42%, and Tier 3 – 25% • By Designation: C-level – 29%, Director-level – 23%, and Others – 48% • By Region: North America – 35%, Europe – 30%, APAC –26%, Rest of the World –9%
The prominent players in this market include Oracle Corporation (US), Parexel International Corporation (US), Dassault Systèmes (France), Clario (US), Datatrak International (US), Signant Health (US), 4G Clinical (US), MaxisIT (US), IBM Watson Health (US), eClinical Solutions LLC (US), Veeva Systems (US), Research Manager (US), Saama Technologies, LLC (US), Mednet (US), Anju Software, Inc (US), Medrio, Inc. (US), Castor (US), Clinipace (US), ArisGlobal (US), Quretec Ltd. (Estonia), OpenClinica, LLC (US), Advarra (US), RealTime Software Solutions, LLC (US), YPrime LLC. (US) and Vial (US).
Research Coverage
This report studies the eClinical Solutions market based on product, delivery mode, clinical trial phases, end users and region. It provides detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing the growth of this market and the factors impacting market dynamics. The report includes in-depth competitive analysis and the product matrix of the prominent players in this market, along with their company profiles, product portfolios, recent developments (mergers, acquisitions, partnerships, collaborations, etc.), and key business strategies. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments in different geographies.
Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
목차
1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION 45
1.2.1 INCLUSIONS AND EXCLUSIONS 46
1.2.2 MARKET SEGMENTATION 47
1.2.3 GEOGRAPHIES COVERED 47
1.2.4 YEARS CONSIDERED 48
1.3 CURRENCY CONSIDERED 48
1.4 LIMITATIONS 48
1.5 MAJOR MARKET STAKEHOLDERS 49
1.6 SUMMARY OF CHANGES 49
2 RESEARCH METHODOLOGY 51
2.1 RESEARCH APPROACH 51
2.2 RESEARCH METHODOLOGY STEPS 51
FIGURE 1 ECLINICAL SOLUTIONS MARKET: RESEARCH METHODOLOGY 51
2.3 RESEARCH METHODOLOGY DESIGN 52
FIGURE 2 ECLINICAL SOLUTIONS MARKET: RESEARCH DESIGN 52
2.3.1 SECONDARY DATA 53
2.3.1.1 Secondary sources 54
2.3.2 PRIMARY DATA 55
FIGURE 3 PRIMARY SOURCES 55
2.3.2.1 Insights from primary experts 56
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 57
2.4 MARKET SIZE ESTIMATION 57
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 57
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 58
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION 59
FIGURE 8 REVENUE ANALYSIS OF TOP 3 PUBLIC COMPANIES IN ECLINICAL SOLUTIONS MARKET (2021) 59
FIGURE 9 BOTTOM-UP APPROACH 60
FIGURE 10 ECLINICAL SOLUTIONS MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 61
FIGURE 11 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 62
FIGURE 12 TOP-DOWN APPROACH 62
2.5 MARKET BREAKDOWN & DATA TRIANGULATION 63
FIGURE 13 DATA TRIANGULATION METHODOLOGY 63
2.6 STUDY ASSUMPTIONS 64
2.7 LIMITATIONS 64
2.7.1 METHODOLOGY-RELATED LIMITATIONS 64
2.7.2 SCOPE-RELATED LIMITATIONS 64
2.8 RISK ASSESSMENT 65
TABLE 1 ECLINICAL SOLUTIONS MARKET: RISK ASSESSMENT 65
2.9 RECESSION IMPACT ON ECLINICAL SOLUTIONS MARKET 65
TABLE 2 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH) 66
TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 66
TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 66
3 EXECUTIVE SUMMARY 67
FIGURE 14 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 67
FIGURE 15 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2022 VS. 2027 (USD MILLION) 68
FIGURE 16 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022 VS. 2027 (USD MILLION) 69
FIGURE 17 ECLINICAL SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 69
FIGURE 18 ECLINICAL SOLUTIONS MARKET: REGIONS COVERED (USD MILLION) 70
4 PREMIUM INSIGHTS 71
4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW 71
FIGURE 19 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 71
4.2 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE & COUNTRY (2021) 72
FIGURE 20 WEB-HOSTED DELIVERY MODEL ACCOUNTED FOR LARGEST SHARE IN 2021 72
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES 72
FIGURE 21 CHINA IS EXPECTED TO ACCOUNT FOR HIGHEST GROWTH RATE DURING FORECAST PERIOD 72
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 73
FIGURE 22 ECLINICAL SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 73
5.2.1 DRIVERS 74
5.2.1.1 Rising operational costs and regulatory requirements associated with clinical research studies 74
5.2.1.2 Growing adoption of novel software solutions in clinical research 74
5.2.1.3 Favorable government support and funding for clinical trials 75
5.2.1.4 Rising need for improved data standardization 75
5.2.1.5 Increasing R&D expenditure on drug development by pharma-biotech companies 76
5.2.2 RESTRAINTS 76
5.2.2.1 High implementation costs associated with eClinical solutions 76
5.2.2.2 Shortage of skilled professionals 77
5.2.2.3 Limited awareness among researchers 77
5.2.3 OPPORTUNITIES 77
5.2.3.1 Increasing clinical trials in emerging countries 77
5.2.3.2 Growing outsourcing of clinical trial processes to CROs 78
5.2.3.3 Gradual shift from manual data interpretation to real-time data analysis 78
5.2.4 CHALLENGES 79
5.2.4.1 Limited adoption in emerging countries due to budgetary constraints 79
5.2.4.2 Concerns regarding software reliability 79
5.2.4.3 Issues associated with patient privacy 79
5.3 ECLINICAL SOLUTIONS MARKET: ECOSYSTEM ANALYSIS 80
FIGURE 23 ECOSYSTEM ANALYSIS 80
5.4 CASE STUDIES 80
5.4.1 YORK TEACHING HOSPITAL EXPEDITES DATA CAPTURE PROCESSING DURING PHASE III CLINICAL STUDY 80
5.4.2 LSHTM AND MENAFRICAR INCORPORATE DATA CAPTURE SOFTWARE TO STUDY MENINGOCOCCAL CARRIAGE IN AFRICA 80
5.4.3 CLINICAL TRIALS GROUP AT UCL UTILIZES EDC SYSTEM TO CAPTURE AND VERIFY PATIENT FEEDBACK 81
5.5 VALUE CHAIN ANALYSIS 81
FIGURE 24 ECLINICAL SOLUTIONS MARKET: VALUE CHAIN ANALYSIS 81
5.6 PORTER’S FIVE FORCES ANALYSIS 82
TABLE 5 HIGH CAPITAL INVESTMENTS TO RESTRICT ENTRY OF NEW PLAYERS 82
5.6.1 THREAT OF NEW ENTRANTS 82
5.6.2 THREAT OF SUBSTITUTES 82
5.6.3 BARGAINING POWER OF BUYERS 82
5.6.4 BARGAINING POWER OF SUPPLIERS 82
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.7 REGULATORY LANDSCAPE 83
5.7.1 NORTH AMERICA 83
5.7.2 EUROPE 84
5.7.3 ASIA PACIFIC 84
5.7.4 MIDDLE EAST & AFRICA 85
5.7.5 LATIN AMERICA 85
5.8 TECHNOLOGY ANALYSIS 85
TABLE 6 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS 85
5.9 INDUSTRY TRENDS 86
5.9.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRAILS 86
5.9.2 GROWING ADOPTION OF TELEMEDICINE 87
5.9.3 IMPACT OF BIG DATA ON HEALTHCARE 87
5.10 PRICING ANALYSIS 87
5.10.1 AVERAGE SELLING PRICE TREND ANALYSIS 88
TABLE 7 AVERAGE SELLING PRICE OF ECLINICAL SOLUTIONS, BY LICENSE 88
5.11 KEY CONFERENCES AND EVENTS FROM 2022−2023 88
TABLE 8 ECLINICAL SOLUTIONS MARKET: LIST OF CONFERENCES AND EVENTS FROM 2022−2023 88
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 89
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS AMONG END USERS 89
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS AMONG END USERS 89
5.12.1 BUYING CRITERIA 90
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 90
TABLE 10 KEY BUYING CRITERIA FOR END USERS 90
6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT 91
6.1 INTRODUCTION 92
TABLE 11 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 92
TABLE 12 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 93
6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS 93
6.2.1 UTILIZATION OF COST-EFFECTIVE ECLINICAL SOLUTIONS INTEGRATED WITH EDC & CDM SYSTEMS TO DRIVE MARKET 93
TABLE 13 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION) 94
TABLE 14 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 15 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 95
TABLE 16 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 17 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 95
TABLE 18 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 19 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 96
TABLE 20 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 96
6.3 CLINICAL TRIAL MANAGEMENT SYSTEMS 97
6.3.1 ABILITY TO BE DEPLOYED AS A SECURE WEB APPLICATION TO DRIVE UPTAKE 97
TABLE 21 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION) 97
TABLE 22 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 23 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 98
TABLE 24 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 25 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 99
TABLE 26 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 27 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 99
TABLE 28 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 100
6.4 CLINICAL ANALYTICS PLATFORMS 100
6.4.1 ABILITY TO AUTOMATE CLINICAL DEVELOPMENT ACTIVITIES TO DRIVE MARKET 100
TABLE 29 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY REGION, 2016–2019 (USD MILLION) 101
TABLE 30 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY REGION, 2020–2027 (USD MILLION) 101
TABLE 31 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION) 101
TABLE 32 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 33 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION) 102
TABLE 34 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 35 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION) 103
TABLE 36 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION) 103
6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS 103
6.5.1 EFFECTIVE MANAGEMENT OF INVENTORY MONITORING AND RANDOMIZED PATIENT POOLS TO DRIVE ADOPTION 103
TABLE 37 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION) 104
TABLE 38 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION) 104
TABLE 39 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 104
TABLE 40 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 41 EUROPE: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 105
TABLE 42 EUROPE: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 43 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 106
TABLE 44 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.6 CLINICAL DATA INTEGRATION PLATFORMS 106
6.6.1 ABILITY TO OPTIMIZE SECURE EXCHANGE OF EHR ON A USER-FRIENDLY GUI TO FUEL MARKET 106
TABLE 45 ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY REGION, 2016–2019 (USD MILLION) 107
TABLE 46 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL INTEGRATION PLATFORMS, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 47 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION) 108
TABLE 48 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 49 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION) 108
TABLE 50 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 51 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION) 109
TABLE 52 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION) 109
6.7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS 110
6.7.1 INCREASING ADOPTION OF EPRO SOLUTIONS AND EDIARIES AMONG PHARMA COMPANIES TO DRIVE UPTAKE 110
TABLE 53 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY REGION, 2016–2019 (USD MILLION) 110
TABLE 54 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 55 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 111
TABLE 56 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 57 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 111
TABLE 58 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 59 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 112
TABLE 60 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 112
6.8 SAFETY SOLUTIONS 113
6.8.1 ABILITY TO STREAMLINE SAFETY PROCESSING PROCESSES DURING CLINICAL TRIALS TO SUPPORT MARKET GROWTH 113
TABLE 61 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY REGION, 2016–2019 (USD MILLION) 113
TABLE 62 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY REGION, 2020–2027 (USD MILLION) 113
TABLE 63 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 114
TABLE 64 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 65 EUROPE: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 114
TABLE 66 EUROPE: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 67 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 115
TABLE 68 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 115
6.9 ELECTRONIC TRIAL MASTER FILE SYSTEMS 116
6.9.1 RAPID SEARCH AND RETRIEVAL OF CLINICAL TRIAL DOCUMENTS WITH ETMF TO FUEL MARKET 116
TABLE 69 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY REGION, 2016–2019 (USD MILLION) 116
TABLE 70 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 71 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 117
TABLE 72 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 73 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 117
TABLE 74 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 75 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 118
TABLE 76 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 118
6.10 ELECTRONIC CONSENT SOLUTIONS 119
6.10.1 ABILITY TO ENSURE ADHERENCE TO ICF REGULATIONS TO INCREASE ADOPTION 119
TABLE 77 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY REGION, 2016–2019 (USD MILLION) 119
TABLE 78 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY REGION, 2020–2027 (USD MILLION) 119
TABLE 79 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 120
TABLE 80 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 81 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 120
TABLE 82 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 83 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION) 121
TABLE 84 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
6.11 REGULATORY INFORMATION MANAGEMENT SYSTEMS 122
6.11.1 ABILITY TO ASSIST RESEARCHERS IN CENTRALIZING REGULATORY INFORMATION FOR OPTIMAL STANDARDIZATION TO DRIVE MARKET 122
TABLE 85 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION) 122
TABLE 86 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION) 122
TABLE 87 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 123
TABLE 88 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 89 EUROPE: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 123
TABLE 90 EUROPE: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 91 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION) 124
TABLE 92 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION) 124
6.12 OTHER ECLINICAL SOLUTIONS 125
TABLE 93 OTHER ECLINICAL SOLUTIONS MARKET, BY REGION, 2016–2019 (USD MILLION) 125
TABLE 94 OTHER ECLINICAL SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 125
TABLE 95 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 125
TABLE 96 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 97 EUROPE: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 126
TABLE 98 EUROPE: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 99 ASIA PACIFIC: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 127
TABLE 100 ASIA PACIFIC: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127
7 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE 128
7.1 INTRODUCTION 129
TABLE 101 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 129
TABLE 102 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 129
7.2 WEB-HOSTED MODELS 130
7.2.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET 130
TABLE 103 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY REGION, 2016–2019 (USD MILLION) 130
TABLE 104 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY REGION, 2020–2027 (USD MILLION) 130
TABLE 105 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 131
TABLE 106 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTEL MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 107 EUROPE: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 131
TABLE 108 EUROPE: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 109 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 132
TABLE 110 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 132
7.3 LICENSED ENTERPRISE MODELS 133
7.3.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 133
TABLE 111 ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY REGION, 2016–2019 (USD MILLION) 133
TABLE 112 ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY REGION, 2020–2027 (USD MILLION) 134
TABLE 113 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 134
TABLE 114 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 115 EUROPE: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 135
TABLE 116 EUROPE: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 117 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 135
TABLE 118 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 136
7.4 CLOUD-BASED SOLUTIONS 136
7.4.1 REMOTE CENTRALIZED ACCESS WITH REAL-TIME ANALYSIS TO DRIVE MARKET 136
TABLE 119 ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY REGION, 2016–2019 (USD MILLION) 137
TABLE 120 ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY REGION, 2020–2027 (USD MILLION) 137
TABLE 121 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 137
TABLE 122 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 123 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 138
TABLE 124 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 125 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016–2019 (USD MILLION) 139
TABLE 126 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 139
8 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE 140
8.1 INTRODUCTION 141
TABLE 127 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 141
TABLE 128 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 141
8.2 PHASE I CLINICAL TRIALS 142
8.2.1 ADOPTION OF EDC & CDM SYSTEMS IN PHASE I STUDIES TO DRIVE MARKET 142
TABLE 129 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY REGION, 2016–2019 (USD MILLION) 142
TABLE 130 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY REGION, 2020–2027 (USD MILLION) 142
TABLE 131 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2016–2019 (USD MILLION) 143
TABLE 132 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 133 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2016–2019 (USD MILLION) 143
TABLE 134 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2020–2027 (USD MILLION) 144
TABLE 135 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2016–2019 (USD MILLION) 144
TABLE 136 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2020–2027 (USD MILLION) 144
8.3 PHASE II CLINICAL TRIALS 145
8.3.1 UTILIZATION OF ECLINICAL SOLUTIONS IN STREAMLINING PHASE II TRIALS TO BOOST MARKET 145
TABLE 137 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY REGION, 2016–2019 (USD MILLION) 145
TABLE 138 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY REGION, 2020–2027 (USD MILLION) 146
TABLE 139 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2016–2019 (USD MILLION) 146
TABLE 140 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 141 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2016–2019 (USD MILLION) 147
TABLE 142 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 143 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2016–2019 (USD MILLION) 147
TABLE 144 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2020–2027 (USD MILLION) 148
8.4 PHASE III CLINICAL TRIALS 148
8.4.1 INVOLVEMENT OF A LARGE PATIENT POPULATION TO DRIVE MARKET 148
TABLE 145 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY REGION, 2016–2019 (USD MILLION) 149
TABLE 146 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 147 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2016–2019 (USD MILLION) 149
TABLE 148 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 149 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2016–2019 (USD MILLION) 150
TABLE 150 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 151 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2016–2019 (USD MILLION) 151
TABLE 152 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2020–2027 (USD MILLION) 151
8.5 PHASE IV CLINICAL TRIALS 151
8.5.1 RISING DEMAND FOR POST-MARKETING SURVEILLANCE TO SUPPORT MARKET GROWTH 151
TABLE 153 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY REGION, 2016–2019 (USD MILLION) 152
TABLE 154 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY REGION, 2020–2027 (USD MILLION) 152
TABLE 155 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2016–2019 (USD MILLION) 152
TABLE 156 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 157 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2016–2019 (USD MILLION) 153
TABLE 158 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 159 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2016–2019 (USD MILLION) 154
TABLE 160 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2020–2027 (USD MILLION) 154
9 ECLINICAL SOLUTIONS MARKET, BY END USER 155
9.1 INTRODUCTION 156
TABLE 161 ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 156
TABLE 162 ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 156
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 157
9.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 157
TABLE 163 ECLINICAL SOLUTIONS MARKET SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2016–2019 (USD MILLION) 157
TABLE 164 ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 158
TABLE 165 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION) 158
TABLE 166 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 167 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION) 159
TABLE 168 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 169 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION) 159
TABLE 170 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 160
9.3 CONTRACT RESEARCH ORGANIZATIONS 160
9.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 160
TABLE 171 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2016–2019 (USD MILLION) 161
TABLE 172 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 161
TABLE 173 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2019 (USD MILLION) 161
TABLE 174 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION) 162
TABLE 175 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2019 (USD MILLION) 162
TABLE 176 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 162
TABLE 177 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2019 (USD MILLION) 163
TABLE 178 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 163
9.4 CONSULTANCY SERVICE COMPANIES 163
9.4.1 GROWING COLLABORATIONS FOR CDM BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET 163
TABLE 179 ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY REGION, 2016–2019 (USD MILLION) 164
TABLE 180 ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY REGION, 2020–2027 (USD MILLION) 164
TABLE 181 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION) 164
TABLE 182 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 165
TABLE 183 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION) 165
TABLE 184 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 165
TABLE 185 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION) 166
TABLE 186 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
9.5 MEDICAL DEVICE MANUFACTURERS 166
9.5.1 UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL MARKET 166
TABLE 187 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2016–2019 (USD MILLION) 167
TABLE 188 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2020–2027 (USD MILLION) 167
TABLE 189 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016–2019 (USD MILLION) 167
TABLE 190 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 191 EUROPE: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016–2019 (USD MILLION) 168
TABLE 192 EUROPE: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 193 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016–2019 (USD MILLION) 169
TABLE 194 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020–2027 (USD MILLION) 169
9.6 HOSPITALS 169
9.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET 169
TABLE 195 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY REGION, 2016–2019 (USD MILLION) 170
TABLE 196 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 170
TABLE 197 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016–2019 (USD MILLION) 170
TABLE 198 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 199 EUROPE: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016–2019 (USD MILLION) 171
TABLE 200 EUROPE: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 201 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016–2019 (USD MILLION) 172
TABLE 202 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 172
9.7 ACADEMIC & RESEARCH INSTITUTES 172
9.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 172
TABLE 203 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016–2019 (USD MILLION) 173
TABLE 204 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 173
TABLE 205 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2019 (USD MILLION) 173
TABLE 206 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 207 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2019 (USD MILLION) 174
TABLE 208 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 209 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2019 (USD MILLION) 175
TABLE 210 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 175
10 ECLINICAL SOLUTIONS MARKET, BY REGION 176
10.1 INTRODUCTION 177
TABLE 211 ECLINICAL SOLUTIONS MARKET, BY REGION, 2016–2019 (USD MILLION) 177
TABLE 212 ECLINICAL SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 177
10.2 NORTH AMERICA 178
FIGURE 27 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SNAPSHOT 179
TABLE 213 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 180
TABLE 214 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 180
TABLE 215 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 180
TABLE 216 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 181
TABLE 217 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 181
TABLE 218 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 182
TABLE 219 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 182
TABLE 220 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 182
TABLE 221 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 183
TABLE 222 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 183
10.2.1 NORTH AMERICA: RECESSION IMPACT 183
10.2.2 US 184
10.2.2.1 Rising government funding for pharmaceutical R&D to drive market 184
FIGURE 28 DISTRIBUTION OF R&D COMPANIES BY COUNTRY/REGION (2021 VS. 2022) 185
TABLE 223 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 186
TABLE 224 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 187
TABLE 225 US: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 187
TABLE 226 US: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 188
TABLE 227 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 188
TABLE 228 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 188
TABLE 229 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 189
TABLE 230 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 189
10.2.3 CANADA 189
10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market 189
TABLE 231 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 190
TABLE 232 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 191
TABLE 233 CANADA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 191
TABLE 234 CANADA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 192
TABLE 235 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 192
TABLE 236 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 192
TABLE 237 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 193
TABLE 238 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 193
10.3 EUROPE 193
TABLE 239 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 194
TABLE 240 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 241 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 195
TABLE 242 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 196
TABLE 243 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 196
TABLE 244 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 197
TABLE 245 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 197
TABLE 246 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 197
TABLE 247 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 198
TABLE 248 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 198
10.3.1 EUROPE: RECESSION IMPACT 198
10.3.2 GERMANY 199
10.3.2.1 High number of sponsored clinical trials to drive uptake of eClinical solutions 199
TABLE 249 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 200
TABLE 250 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 201
TABLE 251 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 201
TABLE 252 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 202
TABLE 253 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 202
TABLE 254 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 202
TABLE 255 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 203
TABLE 256 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 203
10.3.3 UK 203
10.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market 203
TABLE 257 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 204
TABLE 258 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 205
TABLE 259 UK: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 205
TABLE 260 UK: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 206
TABLE 261 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 206
TABLE 262 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 206
TABLE 263 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 207
TABLE 264 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 207
10.3.4 FRANCE 207
10.3.4.1 Growing R&D pipeline for oncology trials to drive market 207
TABLE 265 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 208
TABLE 266 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 209
TABLE 267 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 209
TABLE 268 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 210
TABLE 269 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 210
TABLE 270 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 210
TABLE 271 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 211
TABLE 272 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 211
10.3.5 ITALY 211
10.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake 211
TABLE 273 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022) 212
TABLE 274 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 212
TABLE 275 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 213
TABLE 276 ITALY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 213
TABLE 277 ITALY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 214
TABLE 278 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 214
TABLE 279 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 214
TABLE 280 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 215
TABLE 281 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 215
10.3.6 SPAIN 215
10.3.6.1 Established network of research centers to propel market 215
TABLE 282 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 216
TABLE 283 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 217
TABLE 284 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 217
TABLE 285 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 218
TABLE 286 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 218
TABLE 287 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 218
TABLE 288 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 219
TABLE 289 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 219
10.3.7 REST OF EUROPE 219
TABLE 290 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 220
TABLE 291 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 292 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 221
TABLE 293 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 222
TABLE 294 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 222
TABLE 295 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 222
TABLE 296 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 223
TABLE 297 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 223
10.4 ASIA PACIFIC 224
FIGURE 29 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET SNAPSHOT 224
10.4.1 ASIA PACIFIC: RECESSION IMPACT 225
TABLE 298 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 226
TABLE 299 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 226
TABLE 300 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 227
TABLE 301 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 228
TABLE 302 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 228
TABLE 303 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 229
TABLE 304 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 229
TABLE 305 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 229
TABLE 306 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 230
TABLE 307 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 230
10.4.2 CHINA 230
10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market 230
TABLE 308 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 231
TABLE 309 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 232
TABLE 310 CHINA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 232
TABLE 311 CHINA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 233
TABLE 312 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 233
TABLE 313 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 233
TABLE 314 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 234
TABLE 315 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 234
10.4.3 JAPAN 234
10.4.3.1 Established clinical trial infrastructure and biomedical research capabilities to support market growth 234
TABLE 316 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 235
TABLE 317 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 236
TABLE 318 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 236
TABLE 319 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 237
TABLE 320 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 237
TABLE 321 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 237
TABLE 322 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 238
TABLE 323 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 238
10.4.4 INDIA 238
10.4.4.1 Growing pharmaceutical industry to fuel uptake of eClinical solutions 238
TABLE 324 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 239
TABLE 325 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 240
TABLE 326 INDIA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 240
TABLE 327 INDIA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 241
TABLE 328 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 241
TABLE 329 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 241
TABLE 330 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 242
TABLE 331 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 242
10.4.5 REST OF ASIA PACIFIC 242
TABLE 332 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 243
TABLE 333 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 244
TABLE 334 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 244
TABLE 335 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 245
TABLE 336 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 245
TABLE 337 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 245
TABLE 338 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 246
TABLE 339 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 246
10.5 REST OF THE WORLD 246
TABLE 340 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 247
TABLE 341 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 248
TABLE 342 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION) 248
TABLE 343 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION) 249
TABLE 344 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION) 249
TABLE 345 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION) 249
TABLE 346 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION) 250
TABLE 347 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 250
10.5.1 REST OF THE WORLD: RECESSION IMPACT 251
11 COMPETITIVE LANDSCAPE 252
11.1 INTRODUCTION 252
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 252
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 252
11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 254
FIGURE 30 ECLINICAL SOLUTIONS MARKET: KEY PLAYERS 254
11.4 MARKET RANKING ANALYSIS (2021) 254
FIGURE 31 ECLINICAL SOLUTIONS MARKET: COMPANY RANKS (2021) 254
11.5 COMPANY EVALUATION QUADRANT 255
11.5.1 STARS 256
11.5.2 EMERGING LEADERS 256
11.5.3 PERVASIVE PLAYERS 256
11.5.4 PARTICIPANTS 256
FIGURE 32 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021) 257
11.6 ECLINICAL SOLUTIONS MARKET: COMPETITIVE EVALUATION QUADRANT FOR SMES 258
11.6.1 PROGRESSIVE COMPANIES 258
11.6.2 STARTING BLOCKS 258
11.6.3 RESPONSIVE COMPANIES 258
11.6.4 DYNAMIC COMPANIES 258
FIGURE 33 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT FOR SMES (2021) 259
11.7 COMPETITIVE BENCHMARKING 260
FIGURE 34 ECLINICAL SOLUTIONS MARKET: OVERALL FOOTPRINT OF 15 COMPANIES 260
TABLE 348 ECLINICAL SOLUTIONS MARKET: COMPANY PRODUCT FOOTPRINT 260
TABLE 349 ECLINICAL SOLUTIONS MARKET: END USER FOOTPRINT 261
TABLE 350 ECLINICAL SOLUTIONS MARKET: COMPANY REGIONAL FOOTPRINT 262
11.8 COMPETITIVE SITUATIONS AND TRENDS 263
11.8.1 PRODUCT AND SERVICE LAUNCHES 263
TABLE 351 PRODUCT AND SERVICE LAUNCHES (2019−2022) 263
11.8.2 DEALS 264
TABLE 352 DEALS (2019−2022) 264
12 COMPANY PROFILES 265
12.1 KEY PLAYERS 265
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ORACLE CORPORATION 265
TABLE 353 ORACLE CORPORATION: BUSINESS OVERVIEW 265
FIGURE 35 ORACLE CORPORATION: COMPANY SNAPSHOT (2022) 266
12.1.2 DASSAULT SYSTÈMES 269
TABLE 354 DASSAULT SYSTÈMES: BUSINESS OVERVIEW 269
FIGURE 36 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2021) 270
12.1.3 PAREXEL INTERNATIONAL CORPORATION 274
TABLE 355 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 274
12.1.4 CLARIO 277
TABLE 356 CLARIO: BUSINESS OVERVIEW 277
12.1.5 DATATRAK INT. 279
TABLE 357 DATATRAK INT.: BUSINESS OVERVIEW 279
FIGURE 37 DATATRAK INT.: COMPANY SNAPSHOT (2021) 279
12.1.6 SIGNANT HEALTH (CRF HEALTH) 281
TABLE 358 SIGNANT HEALTH: BUSINESS OVERVIEW 281
12.1.7 MAXISIT INC. 283
TABLE 359 MAXISIT INC.: BUSINESS OVERVIEW 283
12.1.8 4G CLINICAL 285
TABLE 360 4G CLINICAL: BUSINESS OVERVIEW 285
12.1.9 ECLINICAL SOLUTIONS LLC. 286
TABLE 361 ECLINICAL SOLUTIONS: BUSINESS OVERVIEW 286
12.1.10 VEEVA SYSTEMS 288
TABLE 362 VEEVA SYSTEMS: BUSINESS OVERVIEW 288
FIGURE 38 VEEVA SYSTEMS: COMPANY SNAPSHOT (2021) 289
12.2 OTHER PLAYERS 291
12.2.1 RESEARCHMANAGER 291
12.2.2 SAAMA TECHNOLOGIES 291
12.2.3 MEDNET 292
12.2.4 ANJU SOFTWARE (PORTFOLIO COMPANY OF ABRY PARTNERS) 292
12.2.5 MEDRIO, INC. 293
12.2.6 CASTOR 294
12.2.7 CLINIPACE 294
12.2.8 IBM WATSON HEALTH 295
12.2.9 ARISGLOBAL 295
12.2.10 QURETEC LTD. 296
12.2.11 OPENCLINICA, LLC. 296
12.2.12 ADVARRA 297
12.2.13 REALTIME SOFTWARE SOLUTIONS, LLC 298
12.2.14 YPRIME LLC. 298
12.2.15 VIAL 299
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 300
13.1 DISCUSSION GUIDE 300
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 304
13.3 CUSTOMIZATION OPTIONS 306
13.4 RELATED REPORTS 306
13.5 AUTHOR DETAILS 307